A 38-year-old woman with acute promyelocytic leukemia (APL) presents to the emergency department with severe bleeding. She has petechiae, gum bleeding, and hemoptysis. Laboratory investigations reveal: Hb 7.2 g/dL, platelet count 18,000/μL, PT 18 seconds (control 12), aPTT 52 seconds (control 35), fibrinogen 85 mg/dL (normal 200–400), D-dimer markedly elevated at 8.5 μg/mL (normal <0.5). Blood smear shows abnormal promyelocytes with Auer rods. What is the most likely diagnosis?

Explanation

## Diagnosis: DIC Secondary to APL ### Clinical Context APL (acute promyelocytic leukemia, FAB M3) is the most thrombogenic hematologic malignancy and the classic trigger for DIC in hematology. The combination of: - Acute leukemia diagnosis (APL with Auer rods on smear) - Severe bleeding manifestations (petechiae, gum bleeding, hemoptysis) - Profound thrombocytopenia - Coagulopathy (prolonged PT/aPTT) - Hypofibrinogenemia (85 mg/dL) - Markedly elevated D-dimer All point unequivocally to **DIC**. ### Pathophysiology of DIC in APL **Key Point:** APL cells release tissue factor (TF) and cancer procoagulant, triggering extrinsic pathway activation and widespread thrombin generation. 1. **Tissue Factor Release** — APL blasts express high levels of TF on their surface and in cytoplasmic granules. 2. **Thrombin Burst** — Uncontrolled TF-mediated activation of Factor X → Factor Xa → prothrombin → thrombin. 3. **Platelet Consumption** — Thrombin activates platelets → microthrombi formation → thrombocytopenia. 4. **Fibrin Deposition** — Widespread fibrin clot formation in microvasculature. 5. **Secondary Fibrinolysis** — Plasminogen activation → plasmin → fibrin degradation → elevated D-dimer and low fibrinogen. ### DIC Scoring (ISTH Criteria) | Parameter | Finding | Points | |-----------|---------|--------| | Platelet count | 18,000/μL (< 50,000) | 1 | | D-dimer/FDP elevation | Markedly elevated (> 4× ULN) | 3 | | PT prolongation | 18 sec (> 3 sec above control) | 1 | | Fibrinogen | 85 mg/dL (< 100) | 1 | | **Total Score** | | **≥ 5** = **Compatible with overt DIC** | This patient scores **6/10**, meeting criteria for **overt DIC**. ### Laboratory Pattern in DIC **High-Yield:** The **consumption coagulopathy** pattern is pathognomonic: - ↓ Platelets (consumption in microthrombi) - ↓ Fibrinogen (consumption + secondary fibrinolysis) - ↑ PT/aPTT (factor consumption) - ↑ D-dimer (secondary fibrinolysis) - ↑ FDP (fibrin degradation products) ### Management **Clinical Pearl:** Treatment of DIC in APL requires **dual approach**: 1. **All-trans retinoic acid (ATRA)** — induces differentiation of APL blasts, reduces TF release within 24–48 hours. 2. **Arsenic trioxide** — synergistic with ATRA; rapidly reduces leukemic burden. 3. **Supportive care** — Fresh frozen plasma (FFP) for fibrinogen replacement, platelet transfusion for severe thrombocytopenia, avoid aggressive diuresis. 4. **Avoid heparin** — Not indicated in APL-DIC; ATRA/ATO address the underlying cause. **Key Point:** Early recognition and treatment of the underlying APL with ATRA/ATO is curative for DIC; mortality has dropped from >80% (pre-ATRA era) to <5% with modern protocols. ### Why This Is a High-Yield Question **High-Yield:** APL-DIC is the **most common and most treatable cause of DIC in hematology**. NEET PG examiners expect recognition of: - APL as a DIC trigger - ISTH DIC scoring - The role of ATRA in reversing DIC - Distinction from other bleeding disorders [cite:Robbins 10e Ch 13; Harrison 21e Ch 110]